We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept


Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain. 
Product Indication Dosage form Strength
Vivifast® Useful in the management of several types of cognitive disorders Nov 2015
Viviflux® Indicated for stroke primary and secondary prevention and for cerebrovascular disorders Sep 2011
Vivimind® Intended to protect memory and cognitive functions in MCI patients Nov 2010
Zolmitriptan Migraine Orodispersable tablets 2.5 and 5 mg
Zonisamide Epilepsy Hard capsules 25, 50 and 100 mg
Zonisamide Epilepsy IR tablets 25, 50, 100, 200 and 300 mg

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.